<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7303642\results\search\testTrace\results.xml">
  <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of" exact="infection" post="with many commonly used immunosuppressive agents remains low, direct"/>
  <result pre="uncertainty. Baseline risk in immune-mediated dermatologic disorders Evaluating the baseline" exact="infection" post="risk of patients isÂ an important aspect of risk"/>
  <result pre="conditions, such as psoriasis and lupus, are associated with increased" exact="infection" post="risk irrespective of exposure to immunomodulatory agents.1,2 Many of"/>
  <result pre="associated with comorbidities known to predict poor outcomes in COVID-19" exact="infection" post="(eg, diabetes and obesity in patients with psoriasis, asthma"/>
  <result pre="was not identified as a significant risk factor for primary" exact="infection" post="or death,5,6 and several milder or attenuated cases of"/>
  <result pre="infection or death,5,6 and several milder or attenuated cases of" exact="infection" post="were reported in immunosuppressed populations.7,8 Corroborating this, a National"/>
  <result pre="therapeutic potential of various immunosuppressive and immunomodulatory agents in the" exact="treatment" post="of COVID-19 and the potential associated cytokine storm. Existing"/>
  <result pre="data and relevant trial data are presented below. Data regarding" exact="infection" post="risk and complications of immunosuppressive and immunomodulatory agents Glucocorticoids"/>
  <result pre="and immunomodulatory agents Glucocorticoids Evidence linking systemic corticosteroids to increased" exact="infection" post="risk comes from a meta-analysis of 71 clinical trials,"/>
  <result pre="71 clinical trials, which found an increased overall rate of" exact="infection" post="in patients receiving systemic corticosteroids (relative risk [RR], 1.6;"/>
  <result pre="Corrona registry (Corrona, LLC, Waltham, MA) also found increased overall" exact="infection" post="risk with prednisone &amp;gt;10Â mg/d in patients with rheumatoid"/>
  <result pre="the setting of COVID-19. Methotrexate In clinical trials, methotrexate increased" exact="infection" post="risk in patients with rheumatoid arthritis (risk ratio, 1.25;"/>
  <result pre="clinical trial evaluating the efficacy of low-dose methotrexate for the" exact="treatment" post="of atherosclerosis in patients with cardiovascular disease. Mild infections"/>
  <result pre="(URI) or influenza infections.21 Conclusions A modestly increased risk of" exact="infection" post="associated with methotrexate has been suggested in some studies."/>
  <result pre="uncontrolled, and small case series suggesting potential efficacy in the" exact="treatment" post="of SARS-CoV-2 infection. Although inÂ vitro data suggest chloroquine"/>
  <result pre="available clinical data do not suggest any benefit for theÂ" exact="treatment" post="of patients critically ill with COVID-19.26, 27, 28, 29,"/>
  <result pre="30 Conclusions The current data show no significant risk of" exact="infection" post="or infectious complications when antimalarials are used for the"/>
  <result pre="infection or infectious complications when antimalarials are used for the" exact="treatment" post="of immune-mediated disease and therefore suggest low potential for"/>
  <result pre="However, data supporting the use of antimalarials for prevention or" exact="treatment" post="of COVID-19 are lacking at present, and use of"/>
  <result pre="methotrexate, cyclosporine A had a 58% higher risk of overall" exact="infection" post="(adjusted RR, 1.58; 95% CI, 1.17-2.15). In the same"/>
  <result pre="CI, 1.17-2.15). In the same study, azathioprine had double the" exact="infection" post="risk (RR, 1.78; 95% CI, 0.98-3.25), whereas mycophenolate mofetil"/>
  <result pre="Some authors have suggested the use of cyclosporine in the" exact="treatment" post="of COVID-1937 based on its ability to inhibit coronavirus"/>
  <result pre="Azathioprine, mycophenolate mofetil, and cyclosporine A increase the risk of" exact="infection" post="relative to reference agents such as methotrexate, warranting increased"/>
  <result pre="studies. Conclusions The available data suggest a low risk of" exact="infection" post="associated with the use of apremilast and, therefore, low"/>
  <result pre="trials and long-term extension studies in rheumatoid arthritis reveals serious" exact="infection" post="rates of 2.4 per 100 patient-years,42 comparable to the"/>
  <result pre="systemic therapy in psoriasis, showed an increased risk of overall" exact="infection" post="with tumor necrosis factor (TNF) inhibitors compared with ustekinumab"/>
  <result pre="Of all TNF inhibitors, infliximab had the highest risk of" exact="infection" post="(adjusted riskÂ ratio, 1.71; 95% CI, 1.1-2.65).54 Similarly, data"/>
  <result pre="psoriasis and found no significant increase in URI or influenza" exact="infection" post="rates compared with placebo.57 In contrast, Wan etÂ al58"/>
  <result pre="IL-17 inhibition. The data presented indicate higher rates of overall" exact="infection" post="and URIs with TNF inhibitors; however, ongoing trials investigating"/>
  <result pre="polysaccharide vaccines, with effects lasting up to 6Â months after" exact="treatment" post="with rituximab.68,69 Conclusions The data suggest increased rates of"/>
  <result pre="treatment with rituximab.68,69 Conclusions The data suggest increased rates of" exact="infection" post="and infectious complications associated with the use of rituximab."/>
  <result pre="who receive recurrent rituximab dosing. Dupilumab A comprehensive evaluation of" exact="infection" post="risk with dupilumab was conducted by Eichenfield etÂ al.70"/>
  <result pre="7 randomized controlled trials in atopic dermatitis, which showed similar" exact="infection" post="rates per 100 patient-years in the treatment and placebo"/>
  <result pre="which showed similar infection rates per 100 patient-years in the" exact="treatment" post="and placebo groups. Specifically, the rates of viral URIs"/>
  <result pre="methotrexate. Conclusions Data to date suggest a low risk of" exact="infection" post="with the use of dupilumab and a low potential"/>
  <result pre="Female sex 49 (57) 79 (72) 243 (46.3) Most common" exact="diagnosis" post="PsA: 21 (24) RA: 40 (36) CD: 312 (59.4)"/>
  <result pre="of 112) of patients on IL-12/23 inhibitors. With regards to" exact="infection" post="risk, a case-control study by Damiani etÂ al74 evaluated"/>
  <result pre="of Lombardy, patients on biologics had a higher risk of" exact="testing" post="positive for COVID-19 (OR, 3.43; 95% CI, 2.25-5.73) and"/>
  <result pre="or initiating immunoglobulin therapy, or both. Patients requiring initiation of" exact="treatment" post="We suggest the following: a.On the basis of disease"/>
  <result pre="immunosuppressive agents with a higher known or suspected risk of" exact="infection" post="(see Table II). b.When medically appropriate, opt for short"/>
  <result pre="intensive toxicity/safety monitoring. Patients with active COVID-19 infection, including COVID-19+" exact="testing" post="(even in the absence of symptoms) Although the potential"/>
  <result pre="suggest that, if possible, immunosuppressive therapy be held in patients" exact="testing" post="positive for COVID-19, even if asymptomatic, with the concern"/>
  <result pre="psoriasis: a population-based cohortJ Am Acad Dermatol65620111135114421664719 2HerrintonL.J.LiuL.GoldfienR.MichaelsM.A.TranT.N.Risk of serious" exact="infection" post="for patients with systemic lupus erythematosus starting glucocorticoids with"/>
  <result pre="syndromeAm J Respir Crit Care Med1691200412512814695107 8KimS.-H.KoJ.-H.ParkG.E.Atypical presentations of MERS-CoV" exact="infection" post="in immunocompromised hostsJ Infect Chemother2311201776977328545936 9PrescottJ.FalzaranoD.de WitE.Pathogenicity and viral"/>
  <result pre="taking glucocorticosteroidsRev Infect Dis11619899549632690289 12MigitaK.SasakiY.IshizukaN.Glucocorticoid therapy and the risk of" exact="infection" post="in patients with newly diagnosed autoimmune diseaseMedicine (Baltimore)925201328529323982055 13GreenbergJ.D.ReedG.KremerJ.M.Association"/>
  <result pre="online January 1, 2020:2020.06.22.20137273. 10.1101/2020.06.22.20137273. 15LeeN.Allen ChanK.C.HuiD.S.Effects of early corticosteroid" exact="treatment" post="on plasma SARS-associated Coronavirus RNA concentrations in adult patientsJ"/>
  <result pre="Respir Crit Care Med19762017757767 18LansburyL.RodrigoC.Leonardi-BeeJ.Nguyen-Van-TamJ.LimW.S.Corticosteroids as adjunctive therapy in the" exact="treatment" post="of influenzaCochrane Database Syst Rev222019CD01040630798570 19NiY.-N.ChenG.SunJ.LiangB.-M.LiangZ.-A.The effect of corticosteroids"/>
  <result pre="influenza pneumonia: a systematic review and meta-analysisCrit Care23120199930917856 20IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of" exact="infection" post="with methotrexate therapy in inflammatory diseases: a systematic review"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [e-pub"/>
  <result pre="by chloroquineBiochem Biophys Res Commun3231200426426815351731 26PastickK.A.OkaforE.C.WangF.Review: hydroxychloroquine and chloroquine for" exact="treatment" post="of SARS-CoV-2 (COVID-19)Open Forum Infect Dis742020ofaa13032363212 27MahevasM.TranV.-T.RoumierM.No evidence of"/>
  <result pre="of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19" exact="infection" post="with oxygen requirement: results of a study using routinely"/>
  <result pre="and efficacy of tofacitinib for up to 9.5â€‰years in the" exact="treatment" post="of rheumatoid arthritis: final results of a global, open-label,"/>
  <result pre="findings from the BIOBADADERM RegistryJ Investig Dermatol1372201731332127677836 55KalbR.E.FiorentinoD.F.LebwohlM.G.Risk of serious" exact="infection" post="with biologic and systemic treatment of psoriasis: results from"/>
  <result pre="Investig Dermatol1372201731332127677836 55KalbR.E.FiorentinoD.F.LebwohlM.G.Risk of serious infection with biologic and systemic" exact="treatment" post="of psoriasis: results from the Psoriasis Longitudinal Assessment and"/>
  <result pre="Dermatol82520201217121832199889 57BrownstoneN.D.ThibodeauxQ.G.ReddyV.D.Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis:" exact="infection" post="risk and patient counseling in uncertain timesDermatol Ther (Heidelb)102020339349"/>
  <result pre="(COVID-19) and biologic therapy in psoriasis: infection risk and patient" exact="counseling" post="in uncertain timesDermatol Ther (Heidelb)102020339349 58Wan MT, Shin DB,"/>
  <result pre="rituximab combined with short-term prednisone versus prednisone alone for the" exact="treatment" post="of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label"/>
  <result pre="[e-pub ahead of print]Gastroenterology202010.1053/j.gastro.2020.05.032 74DamianiG.PacificoA.BragazziN.L.MalagoliP.Biologics increase the risk of SARS-CoV-2" exact="infection" post="and hospitalization, but not ICU admission and death: real-life"/>
 </snippets>
</snippetsTree>
